Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.

Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).

[1]  N. Reinmuth,et al.  A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  R. Greil,et al.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.

[3]  David R. Jones,et al.  Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis , 2019, Nature Cell Biology.

[4]  E. Winer,et al.  TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[6]  Susan M. Chang,et al.  Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications , 2019, Neuro-oncology.

[7]  M. Chamberlain,et al.  Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[8]  Salvatore Piscuoglio,et al.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma , 2015, Nature Communications.

[9]  G. Cutter,et al.  Capacity of patients with brain metastases to make treatment decisions , 2015, Psycho-oncology.

[10]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[11]  M. Taphoorn,et al.  Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. , 2015, Neuro-oncology.

[12]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[13]  M. Gnant,et al.  Activity of T-DM1 in Her2-positive breast cancer brain metastases , 2015, Clinical & Experimental Metastasis.

[14]  P. Canney,et al.  A Prospective Randomised Phase III Clinical Trial Testing the Role of Prophylactic Cranial Radiotherapy in Patients Treated with Trastuzumab for Metastatic Breast Cancer - Anglo Celtic VII. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[15]  J. Buckner,et al.  NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Whelan,et al.  Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Crinò,et al.  Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Weil,et al.  Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. , 2015, Neuro-oncology.

[19]  S. Margolin,et al.  CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Wolfgang A Tome,et al.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Robertson,et al.  GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. , 2014, Journal of neurotrauma.

[22]  K. Blackwell,et al.  Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  E. Neuwelt,et al.  Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. , 2014, CNS oncology.

[24]  S. Verma,et al.  Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases , 2014, BMJ Case Reports.

[25]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[26]  A. González-Angulo.  Faculty Opinions recommendation of Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. , 2014 .

[27]  G. Elia,et al.  Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer , 2014, BMC Cancer.

[28]  J. Baselga,et al.  Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  S. Steinberg,et al.  Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner , 2014, Clinical Cancer Research.

[30]  N. Lin,et al.  CNS Metastases in Breast Cancer: Old Challenge, New Frontiers , 2013, Clinical Cancer Research.

[31]  C. Sotiriou,et al.  Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  P. Brown,et al.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. , 2013, Neuro-oncology.

[33]  Erin M. Olson,et al.  Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. , 2013, Breast.

[34]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[35]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[36]  E. Shaw,et al.  Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery , 2012, Journal of Neuro-Oncology.

[37]  A. Niemierko,et al.  Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype , 2012, Breast Cancer Research and Treatment.

[38]  Dirk Rades,et al.  Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline , 2012, Practical radiation oncology.

[39]  J. Polli,et al.  Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer , 2012, Pharmaceutical Research.

[40]  P. Falkai,et al.  microRNA‐34c is a novel target to treat dementias , 2011, The EMBO journal.

[41]  R. Greil,et al.  Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases , 2011, Journal of Neuro-Oncology.

[42]  A. Gabrielli,et al.  Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. , 2011, Journal of neurotrauma.

[43]  Tarek Mekhail,et al.  Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study , 2011, Current oncology reports.

[44]  K. Camphausen,et al.  Brain metastases as preventive and therapeutic targets , 2011, Nature Reviews Cancer.

[45]  L. Collette,et al.  Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  P. Steeg,et al.  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.

[47]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Stephan Saikali,et al.  Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods , 2010, Journal of Neuro-Oncology.

[49]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[50]  M. Gilbert,et al.  The role of chemotherapy in the treatment of patients with brain metastases from solid tumors , 2009, International Journal of Clinical Oncology.

[51]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[52]  M. Gilbert,et al.  Clinical utility of the MDASI-BT in patients with brain metastases. , 2009, Journal of pain and symptom management.

[53]  R. Greil,et al.  Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer , 2009, Clinical Cancer Research.

[54]  A. Vortmeyer,et al.  Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization , 2008, Clinical & Experimental Metastasis.

[55]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[57]  J. Netterville,et al.  A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. , 2007, International journal of radiation oncology, biology, physics.

[58]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[59]  V. Heinemann,et al.  Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. , 2006, Breast.

[60]  C. Swanton,et al.  Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab , 2006, Acta oncologica.

[61]  D. Peereboom.  Chemotherapy in brain metastases. , 2005, Neurosurgery.

[62]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  A. Howell,et al.  Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer , 2004, British Journal of Cancer.

[64]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[66]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.

[67]  L. Deangelis,et al.  Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel , 1995, Cancer.

[68]  O. Dalesio,et al.  Response of brain metastases from breast cancer to systemic chemotherapy , 1992, Cancer.

[69]  W. Lane,et al.  Chemotherapy induces regression of brain metastases in breast carcinoma , 1986, Cancer.

[70]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[71]  M. Mehta,et al.  CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933 , 2015, Journal of Neuro-Oncology.

[72]  L. Collette,et al.  A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Campone,et al.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.

[74]  S. Steinberg,et al.  Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage. , 2012, Cancer research.

[75]  J. Manson,et al.  Prospective Study of , 2007 .

[76]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[77]  N. Dubrawsky.  Cancer statistics , 2022 .